Iconovo has signed a development agreement with Monash University for the development of inhaled oxytocin in ICOone for maternal health.
The agreement verifies the suitability of ICOone for use with innovative pharmaceuticals. Monash University’s Institute of Pharmaceutical Sciences (MIPS) is l